# Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

> **NCT05431270** · PHASE1,PHASE2 · RECRUITING · sponsor: **Phanes Therapeutics** · enrollment: 40 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Mavrostobart (PT199)
- **DRUG:** Tislelizumab
- **DRUG:** Gemcitabine + nab-Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin + Pemetrexed
- **DRUG:** Pembrolizumab + Carboplatin + Pemetrexed

## Key facts

- **NCT ID:** NCT05431270
- **Lead sponsor:** Phanes Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-11
- **Primary completion:** 2027-12
- **Final completion:** 2028-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431270, "Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05431270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*